OCGN · Ocugen, Inc.
$1.02
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“After evaluating these conditions and management's plans, the Company has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$345.89M
Shares
339.11M
Volume · Oct 5
4M
Avg daily vol (3M)
5.84M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.02
Open$1.04
Day$1.01–1.04
52W close$0.99–2.48
Avg vol 30d7.3M
Short int106.1M · 31.3% float · 10.4d
Short vol70%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.58M
Trailing 12 months
Net income (TTM)
−$81.81M
Trailing 12 months
Revenue growth YoY
+8.4%
Year over year
Operating margin
-1,504.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-17.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$98.30M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.0%
Year over year · more shares
Price change (1Y)
-42.4%
Trailing year
Short interest
31.3%
Latest settlement · 10.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−16%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−43%
trailing
YTD return
−24%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +43 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
31.28% of float · ▲ +7.9% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
149 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-57.1M
Balance sheet
$10.2M
net debt
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +43 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
31.28% of float · ▲ +7.9% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
149 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 2%
Range high $2
vs 200-day avg -32%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCGN
this stock
Ocugen, Inc.
|
$345.89M | -24.4% | -100.0% | — | 31.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCGN | +0.0% | -24.4% | -43.0% | -1.0% | -24.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.2% | -24.0% | -55.2% | -1.9% | -37.3% |